WT1 has emerged as one of the most promising targets for AML immunotherapy, because of its oncogenic role in leukaemogenesis, its high expression in the majority of AML cells, and its ability to function as a tumour rejection antigen [97]. The gene discussed is WT1; the disease is acute myeloid leukemia.